Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Saved in:
| Title: | Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. |
|---|---|
| Authors: | Watson, Zachary L.1 (AUTHOR), Yamamoto, Tomomi M.1 (AUTHOR), McMellen, Alexandra2 (AUTHOR), Kim, Hyunmin3 (AUTHOR), Hughes, Connor J.4 (AUTHOR), Wheeler, Lindsay J.5 (AUTHOR), Post, Miriam D.1,6 (AUTHOR), Behbakht, Kian1,5 (AUTHOR), Bitler, Benjamin G.1 (AUTHOR) benjamin.bitler@ucdenver.edu |
| Source: | Clinical Epigenetics. 11/27/2019, Vol. 11 Issue 1, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
